奈达铂对比顺铂同步放化疗治疗II-IVB期鼻咽癌的非劣效性随机III期试验
这项在中国两中心开展的开放标签、非劣效性、随机III期试验,纳入402例II-IVB期非角化性鼻咽癌患者,比较奈达铂与顺铂同步调强放疗的疗效与安全性。主要终点为2年无进展生存率,奈达铂组非劣效于顺铂组,且呕吐、恶心、厌食及严重听力毒性显著更低。
要点
- 奈达铂同步放化疗在2年无进展生存上非劣效于顺铂同步放化疗。
- 奈达铂组3-4级呕吐、恶心、厌食及严重听力毒性显著低于顺铂组。
- 奈达铂组3-4级血小板减少有增高趋势但未达统计学显著。
核心结论
- 奈达铂同步放化疗可作为局部晚期鼻咽癌顺铂同步放化疗的替代双药治疗策略。
研究设计与样本
- 开放标签、非劣效性、随机III期试验,在中国两个中心进行。
- 纳入402例18-65岁非角化性II-IVB期鼻咽癌患者,按1:1随机分配至奈达铂组(n=201)或顺铂组(n=201)。
- 化疗为第1、22、43天静脉给予奈达铂100 mg/m2或顺铂100 mg/m2,共3周期,同步调强放疗。
- 主要终点为2年无进展生存率,非劣效界值为两组差值95%CI上限不超过10%。
关键数值与推荐
- 非劣效性定义为两组2年无进展生存率差值的95%CI上限不超过10%。
临床怎么用
- 对于局部晚期鼻咽癌患者,可考虑使用奈达铂同步放化疗作为顺铂方案的替代,尤其关注顺铂胃肠道及耳毒性风险时。
- 使用奈达铂时需注意监测血小板减少。
局限性
- 开放标签设计,患者和临床医生未对治疗分配设盲。
- 随访时间有限,此次报告为2年无进展生存数据,试验仍在随访中。
- 研究仅在中国两个中心进行,外部推广性需进一步验证。
- 未探索奈达铂用于诱导或辅助化疗、或与其他药物联合的潜在价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cisplatin-based concurrent chemoradiotherapy is currently considered to be the standard treatment regimen for patients with advanced nasopharyngeal carcinoma, but has well known side-effects such as gastrointestinal reactions, nephrotoxicity, and ototoxicity. Nedaplatin was developed to decrease the toxic effects induced by cisplatin, and in this trial we assessed whether a nedaplatin-based concurrent chemoradiotherapy regimen was non-inferior to a cisplatin-based regimen in patients with locoregional, stage II-IVB nasopharyngeal carcinoma. METHODS: We did an open-label, non-inferiority, phase 3, randomised, controlled trial at two centres in China. Patients aged 18-65 years with non-keratinising stage II-IVB (T1-4N1-3 or T3-4N0) nasopharyngeal carcinoma, a Karnofsky score of at least 70, and adequate haematological, renal, and hepatic function were randomly assigned (1:1) to receive intravenously either nedaplatin 100 mg/m2 or cisplatin 100 mg/m2 on days 1, 22, and 43 for three cycles concurrently with intensity-modulated radiotherapy. Randomisation was done manually using a computer-generated random number code and patients were stratified by treatment centre and clinical stage. Patients and clinicians were not masked to treatment allocation. The primary endpoint was progression-free survival at 2 years; non-inferiority was shown if the upper limit of the 95% CI for the difference in 2-year progression-free survival between the two groups did not exceed 10%. Analyses were by both intention to treat and per protocol, including all patients who received at least one complete cycle of chemotherapy. This trial is registered with ClinicalTrials.gov, number NCT01540136, and is currently in follow-up. FINDINGS: Between Jan 16, 2012, and July 16, 2014, we randomly assigned 402 patients to nedaplatin-based (n=201) or cisplatin-based (n=201) concurrent chemoradiotherapy. In the intention-to-treat population, 2-year progression-free survival was 89·9% (95% CI 85·8-94·0) in the cisplatin group and 88·0% (83·5-94·5) in the nedaplatin group, with a difference of 1·9% (95% CI -4·2 to 8·0; pnon-inferiority=0·0048). In the per-protocol analysis (cisplatin group, n=197; nedaplatin group, n=196), 2-year progression-free survival was 89·7% (95% CI 85·4-94·0) in the cisplatin group and 88·7% (84·2-94·5) in the nedaplatin group, with a difference of 1·0% (95% CI -5·2 to 7·0; pnon-inferiority=0·0020). A significantly higher frequency of grade 3 or 4 vomiting (35 [18%] of 198 in the cisplatin group vs 12 [6%] of 200 in the nedaplatin group, p<0·0001), nausea (18 [9%] vs four [2%], p=0·0021), and anorexia (53 [27%] vs 26 [13%], p=0·00070) was observed in the cisplatin group compared with the nedaplatin group. 11 (6%) patients in the nedaplatin group had grade 3 or 4 thrombocytopenia compared with four (2%) in the cisplatin group (p=0·065). Patients in the cisplatin group had a higher frequency of any grade or grade 3 or 4 late auditory or hearing toxicities than did patients in the nedaplatin group (grade 3 or 4: three [2%] in the nedaplatin group vs 11 [6%] in the cisplatin group, p=0·030). No patients died from treatment-related causes. INTERPRETATION: Our findings show that nedaplatin-based concurrent chemoradiotherapy represents an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy for patients with locoregional, advanced nasopharyngeal carcinoma. Further investigations are needed to explore the potential use of this treatment as induction or adjuvant chemotherapy or in combination with other agents. FUNDING: National Key R&D Program of China, National Natural Science Foundation of China, Sun Yat-sen University Clinical Research 5010 Program, Sci-Tech Project Foundation of Guangzhou City, National Key Basic Research Program of China, Special Support Plan of Guangdong Province, Sci-Tech Project Foundation of Guangdong Province, Health & Medical Collaborative Innovation Project of Guangzhou City, National Science & Technology Pillar Program during the Twelfth Five-year Plan Period, PhD Start-up Fund of Natural Science Foundation of Guangdong Province, Cultivation Foundation for the Junior Teachers in Sun Yat-sen University, and Fundamental Research Funds for the Central Universities.
引用
- Tang LQ, Chen DP, Guo L, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018. PMID: 29501366. doi:10.1016/S1470-2045(18)30104-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。